Clinical Trials Logo

Filter by:
NCT ID: NCT02421939 Active, not recruiting - Clinical trials for Leukemia, Acute Myeloid (AML)

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Start date: October 20, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants. This study will also determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

NCT ID: NCT02399124 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Post Marketing Surveillance for PROSENSEā„¢ a Cryotherapy Treatment of Renal Cell Carcinoma

ICE-SECRET
Start date: July 2014
Phase: N/A
Study type: Interventional

This experiment is designed for post marketing data collection of a cryosurgical system [PROSENSEā„¢ of IceCure Medical], for the treatment of renal cell carcinoma (RCC).

NCT ID: NCT02386553 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NURTURE
Start date: May 18, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.

NCT ID: NCT02369731 Active, not recruiting - Clinical trials for Muscular Dystrophy, Duchenne

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Start date: April 30, 2015
Phase:
Study type: Observational [Patient Registry]

This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.

NCT ID: NCT02365597 Active, not recruiting - Urothelial Cancer Clinical Trials

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Start date: April 22, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

NCT ID: NCT02344784 Active, not recruiting - Clinical trials for Attention Deficit Disorder

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder

PPI
Start date: January 2015
Phase: N/A
Study type: Observational

The purpose of this study is to show that Prepulse inhibition test of acoustic startle response is an indicator of objective diagnostic characteristics of attention deficit disorder in children and adolescents. by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in children and adolescents suffering from attention deficit disorder in the relation to the normal function described in the literature. The investigators will try to prove our hypothesis by an experiment that consists of two phases: Phase I (about 25 minutes): The patient will enter the room, will be asked to sit on a chair, and will be asked to look at a computer screen showing silent video of aquarium fish, then the patient will be connected to both the Prepulse inhibition test device and the Galvanic skin response device and pass the tests. Phase II (about 25 minutes): After completion of Phase I, each participant will receive his daily regular dose of methylphenidate and after an hour and a half from taking the drug, will repeat the tests, both the Prepulse inhibition test and the Galvanic skin response test. Duration of the entire experiment is 140 minutes (two hours and twenty minutes).

NCT ID: NCT02316106 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Start date: May 20, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

NCT ID: NCT02308085 Active, not recruiting - Early Breast Cancer Clinical Trials

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

POSITIVE
Start date: December 4, 2014
Phase: N/A
Study type: Interventional

The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. A psycho-oncological companion study on fertility concerns, psychological well-being and decisional conflicts will be conducted in interested Centers.

NCT ID: NCT02304796 Active, not recruiting - Anxiety Disorders Clinical Trials

Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders

Start date: January 2015
Phase: N/A
Study type: Interventional

The current pilot study will examine and compare the effectiveness of two group psychotherapies for mixed anxiety disorders: 1. unified cognitive-behavioral protocol, adapted to a group format. 2. combined cognitive-behavioral and dance/movement therapy. In addition, change in proposed mechanism in each therapy will be examined, along with their association with change in outcome measures during therapy.

NCT ID: NCT02303821 Active, not recruiting - Clinical trials for Acute Lymphoblastic Leukemia (ALL)

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: February 16, 2015
Phase: Phase 1
Study type: Interventional

The purpose of Phase 1b of this study is to: - Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). - Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy. The purpose of Phase 2 of this study is to compare the rate of complete remission (CR) of carfilzomib in combination with vincristine, dexamethasone, PEG asparaginase, daunorubicin (VXLD) at the end of induction therapy to an appropriate external control.